Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst) receptor antagonists perform better than agonists in detecting neuroendocrine tumors (NETs). We performed a prospective phase I/II study to evaluate the sst receptor antagonist 68Ga-OPS202 (68Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid and JR11 = Cpa-c(dCys-Aph(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH2)) for PET imaging. Here, we report the results of phase I of the study. Methods: Patients received 2 single 150-MBq intravenous injections of 68Ga-OPS202 3–4 wk apart (15 μg of peptide at visit 1 and 50 μg at visit 2). At visit 1, a dynamic PET/CT scan over the kidney was obtained during the first 30 min after injection, and static whole-body scans were obtained at 0.5, 1, 2, and 4 h after injection; at visit 2, a static whole-body scan was obtained at 1 h. Blood samples and urine were collected at regular intervals to determine 68Ga-OPS202 pharmacokinetics. Safety, biodistribution, radiation dosimetry, and the most appropriate imaging time point for 68Ga-OPS202 were assessed. Results: Twelve patients with well-differentiated gastroenteropancreatic (GEP) NETs took part in the study. 68Ga-OPS202 cleared rapidly from the blood, with a mean residence time of 2.4 ± 1.1 min/L. The organs with the highest mean dose coefficients were the urinary bladder wall, kidneys, and spleen. The calculated effective dose was 2.4E−02 ± 0.2E−02 mSv/MBq, corresponding to 3.6 mSv, for a reference activity of 150 MBq. Based on total numbers of detected malignant lesions, the optimal time window for the scan was between 1 and 2 h. For malignant liver lesions, the time point at which most patients had the highest mean tumor contrast was 1 h. 68Ga-OPS202 was well tolerated; adverse events were grade 1 or 2, and there were no signals of concern from laboratory blood or urinalysis tests. Conclusion:68Ga-OPS202 showed favorable biodistribution and imaging properties, with optimal tumor contrast between 1 and 2 h after injection. Dosimetry analysis revealed that the dose delivered by 68Ga-OPS202 to organs is similar to that delivered by other 68Ga-labeled sst analogs. Further evaluation of 68Ga-OPS202 for PET/CT imaging of NETs is therefore warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127 · cited 1×
“This difference reflects the higher scanner sensitivity and spatial resolution of PET/CT than of SPECT (6), as well as the higher affinity of 68Ga-DOTATOC for the sst2 receptor (7).”
BackgroundSelf-citationQuantities used in radiological protection
(1991) · Annals of the ICRP · doi:10.1016/0146-6453(91)90066-p · Cited by 435
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Fani, M., Braun, F., Waser, B., Beetschen, K., Cescato, R., Erchegyi, J., Rivier, J. E., Weber, W. A., Maecke, H. R., & Reubi, J. C. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.102764 · Cited by 172 · cited 2×
“For this reason, a small library of sst2 receptor antagonists was developed for PET/CT imaging; of these, we selected OPS202 (NODAGA-JR11; NODAGA 5 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid and JR11 5 Cpac(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2)) because it has demonstrated the highest affinity fo…”
BackgroundSelf-citation
Cited by
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
The somatostatin-secreting pancreatic δ-cell in health and disease
Rorsman, P., & Huising, M. O. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0020-6 · Cited by 259
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
Nicolas, G. P., Schreiter, N., Kaul, F., Uiters, J., Bouterfa, H., Kaufmann, J., Erlanger, T. E., Cathomas, R., Christ, E., Fani, M., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199760 · Cited by 171
“More information can be found in the accompanying paper (15).”
BackgroundSelf-citationRadiolabeled somatostatin analogs-a continuously evolving class of radiopharmaceuticals.
Fani, M., Mansi, R., Nicolas, G. P., & Wild, D. (2022) · Cancers · doi:10.3390/cancers14051172 · Cited by 56
Self-citation
Metadata
- Authors
- Nicolas, G. P., Beykan, S., Bouterfa, H., Kaufmann, J., Bauman, A., Lassmann, M., Reubi, J. C., Rivier, J. E. F., Maecke, H. R., Fani, M., & Wild, D.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-10-12
- Volume
- 59
- Issue
- 6
- Pages
- 909-914
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2762500295
- Cited by
- 91
- References
- 3
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. https://app.cochat.ai/papers/10.2967/jnumed.117.199737
- The paper
- Nicolas, G. P., Beykan, S., Bouterfa, H., Kaufmann, J., Bauman, A., Lassmann, M., Reubi, J. C., Rivier, J. E. F., Maecke, H. R., Fani, M., & Wild, D. (2018). Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.117.199737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.